Send to

Choose Destination
Elife. 2017 Sep 26;6. pii: e26738. doi: 10.7554/eLife.26738.

A potent human neutralizing antibody Fc-dependently reduces established HBV infections.

Li D1,2, He W2, Liu X2,3, Zheng S2, Qi Y2, Li H2, Mao F2,4, Liu J2, Sun Y2, Pan L1,2, Du K2,4, Ye K2, Li W2, Sui J2.

Author information

Peking University-Tsinghua University-National Institute of Biological Sciences Joint Graduate Program, School of Life Sciences, Tsinghua University, Beijing, China.
National Institute of Biological Sciences, Beijing, China.
PTN Joint Graduate Program, College of Life Sciences, Peking University, Beijing, China.
Graduate Program in College of Life Sciences, Beijing Normal University, Beijing, China.


Hepatitis B virus (HBV) infection is a major global health problem. Currently-available therapies are ineffective in curing chronic HBV infection. HBV and its satellite hepatitis D virus (HDV) infect hepatocytes via binding of the preS1 domain of its large envelope protein to sodium taurocholate cotransporting polypeptide (NTCP). Here, we developed novel human monoclonal antibodies that block the engagement of preS1 with NTCP and neutralize HBV and HDV with high potency. One antibody, 2H5-A14, functions at picomolar level and exhibited neutralization-activity-mediated prophylactic effects. It also acts therapeutically by eliciting antibody-Fc-dependent immunological effector functions that impose durable suppression of viral infection in HBV-infected mice, resulting in reductions in the levels of the small envelope antigen and viral DNA, with no emergence of escape mutants. Our results illustrate a novel antibody-Fc-dependent approach for HBV treatment and suggest 2H5-A14 as a novel clinical candidate for HBV prevention and treatment of chronic HBV infection.


Fc receptor; HBV; NTCP; antibody; effector function; immunology; infectious disease; microbiology; mouse; preS1; virus

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for eLife Sciences Publications, Ltd Icon for PubMed Central
Loading ...
Support Center